# EDGAR Filing Document

**Accession Number:** 0001533743
**File Stem:** 0001493152-25-011305
**Filing Date:** 2025-7
**Character Count:** 6653
**Document Hash:** 4024e89c5cb12e0bd966808126c37a24
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-011305.hdr.sgml**: 20250718

**ACCESSION NUMBER**: 0001493152-25-011305

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250718

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250718

**DATE AS OF CHANGE**: 20250718

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Processa Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001533743
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 451539785
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39531
- **FILM NUMBER:** 251134670

**BUSINESS ADDRESS:**
- **STREET 1:** 7380 COCA COLA DRIVE
- **STREET 2:** SUITE 106
- **CITY:** HANOVER
- **STATE:** MD
- **ZIP:** 21076
- **BUSINESS PHONE:** 443-776-3133

**MAIL ADDRESS:**
- **STREET 1:** 7380 COCA COLA DRIVE
- **STREET 2:** SUITE 106
- **CITY:** HANOVER
- **STATE:** MD
- **ZIP:** 21076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Heatwurx, Inc.
- **DATE OF NAME CHANGE:** 20111028

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 18, 2025**

**PROCESSA PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39531** | **45-1539785** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **601 21st Street** **, Suite 300 Vero Beach, FL**  | **32960** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (772) 453-2899**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.0001 par value per share | PCSA | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On July 18, 2025, the Company held its 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Present at the Annual Meeting in person or by proxy were holders of shares of common stock of the Company, representing at least one-third (1/3) of the voting power of the common stock of the Company issued and outstanding and entitled to vote as of the close of business on May 1, 2025, the record date for the Meeting, and constituting a quorum for the transaction of business.

At the Annual Meeting, the shareholders of the Company voted on the following four proposals:

&nbsp;&nbsp;&nbsp;&nbsp;1. The
 election of all six directors to serve until the next Annual Meeting of Shareholders or until their successors have been duly elected
 and qualified based on the following votes:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Shares** | **Shares** | **Shares** | **Shares** |
| Name | For | Against | Abstain | Broker Non-Votes |
| Justin Yorke | 1780123 |  | 166311 | 2035053 |
| George Ng | 1782499 |  | 163935 | 2035053 |
| Khoso Baluch | 1781051 |  | 165383 | 2035053 |
| James Neal | 1782912 |  | 163522 | 2035053 |
| Geraldine Pannu | 1784075 |  | 162359 | 2035053 |
| Dr, David Young | 1812043 |  | 134391 | 2035053 |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. The
 issuance of shares of common stock upon exercise of the Series A and B Warrants sold pursuant to the Securities Purchase Agreements
 entered into on January 27, 2025, in accordance with Nasdaq listing rules was approved based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| Shares | Shares | Shares | Shares |
| For | Against | Abstain | Broker Non-Vote |
| 1646114 | 275707 | 24613 | 2035053 |

---

&nbsp;&nbsp;&nbsp;&nbsp;3. The
 appointment of Cherry Bekaert, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025
 was ratified based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| Shares | Shares | Shares | Shares |
| For | Against | Abstain | Broker Non-Vote |
| 3752298 | 166735 | 62454 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;4. The
 advisory vote relating to compensation of our named executive officers was approved based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| Shares | Shares | Shares | Shares |
| For | Against | Abstain | Broker Non-Vote |
| 1704544 | 224727 | 17163 | 2035053 |

---

---

| | |
|:---|:---|
| **Item 9.01(d)** | **Financial Statements and Exhibits** |

---

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL documents)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PROCESSA PHARMACEUTICALS, INC.** | **PROCESSA PHARMACEUTICALS, INC.** |
| Date: July 18, 2025 | By: | */s/ Russell Skibsted* |
|  |  | Russell Skibsted |
|  |  | Chief Financial Officer |

---